Display options
Cite
Dalaklioglu S, Ozbey G. Role of different types of potassium channels in the relaxation of corpus cavernosum induced by resveratrol. Pharmacogn Mag. 2014;10(37):47-52doi: 10.4103/0973-1296.126658.
Dalaklioglu, S., & Ozbey, G. (2014). Role of different types of potassium channels in the relaxation of corpus cavernosum induced by resveratrol. Pharmacognosy magazine, 10(37), 47-52. https://doi.org/10.4103/0973-1296.126658
Dalaklioglu, Selvinaz, and Ozbey, G. "Role of different types of potassium channels in the relaxation of corpus cavernosum induced by resveratrol." Pharmacognosy magazine vol. 10,37 (2014): 47-52. doi: https://doi.org/10.4103/0973-1296.126658
Dalaklioglu S, Ozbey G. Role of different types of potassium channels in the relaxation of corpus cavernosum induced by resveratrol. Pharmacogn Mag. 2014 Jan;10(37):47-52. doi: 10.4103/0973-1296.126658. PMID: 24696545; PMCID: PMC3969658.
Copy Download .nbib Format: NLM
Share it on

Pharmacogn Mag. 2014 Jan;10(37):47-52. doi: 10.4103/0973-1296.126658.

Role of different types of potassium channels in the relaxation of corpus cavernosum induced by resveratrol.

Pharmacognosy magazine

Selvinaz Dalaklioglu, G Ozbey

Affiliations

  1. Department of Pharmacology, Akdeniz University, Medical Faculty, 07070, Antalya, Turkey.

PMID: 24696545 PMCID: PMC3969658 DOI: 10.4103/0973-1296.126658

Abstract

BACKGROUND: Resveratrol (RVT), one of the most commonly employed dietary polyphenol, is used in traditional Japanese and Chinese medicine for treatment of cardiovascular diseases. Recently, we have shown that RVT has a potent relaxant effect on rat corpus cavernosum via endothelium-dependent and -independent mechanisms.

OBJECTIVE: The present study addressed the question whether different types of potassium channels are involved in the endothelium-dependent and -independent mechanism of corpus cavernosum relaxation induced by RVT.

MATERIALS AND METHODS: Strips of corpus cavernosum from rats were mounted in an organ-bath system for isometric tension studies.

RESULTS: RVT (1-100 μmol/L) produced concentration-dependent relaxation responses in rat corpus cavernosum pre-contracted by phenylephrine. The non-selective potassium channels blocker tetraethylammonium chloride (TEA, 10 mmol/L), ATP-sensitive potassium (KATP) channels blocker glibenclamide (10 μmol/L), and inward rectifier potassium (Kir) channels inhibitor barium chloride (BaCl2, 30 μmol/L) caused a significant inhibition on the relaxation response to RVT, whereas voltage-dependent potassium channels inhibitor 4-aminopyridine (4-AP, 1 mmol/L), and large conductance calcium-activated potassium (BKCa) channels inhibitor iberiotoxin (IbTX, 0.1 μmol/L) did not significantly alter relaxant responses of corpus cavernosum strips to RVT. In addition, relaxant responses to RVT did not significantly inhibited by the combination of selective inhibitors of small and intermediate conductance BKCa channels (0.1 μmol/L charybdotoxin and 1 μmol/L apamin, respectively).

CONCLUSION: These results demonstrated that endothelial small and intermediate conductance BKCa channels are not thought to be an important role in RVT-induced endothelium-dependent relaxation of corpus cavernosum. The endothelium-independent corpus cavernosum relaxation induced by RVT is seems to largely depend on Kir channels and KATP channels in corporal tissue.

Keywords: Corpus cavernosum; potassium channels; relaxation; resveratrol

References

  1. Drugs Today (Barc). 2000 Feb-Mar;36(2-3):147-54 - PubMed
  2. Int J Impot Res. 2013 Sep;25(5):188-93 - PubMed
  3. Drug News Perspect. 2000 Feb;13(1):28-36 - PubMed
  4. Am J Physiol. 1998 Feb;274(2):R541-7 - PubMed
  5. FASEB J. 1989 Oct;3(12):2389-400 - PubMed
  6. Clin Exp Pharmacol Physiol. 2004 Sep;31(9):641-9 - PubMed
  7. Physiol Rev. 1995 Jan;75(1):191-236 - PubMed
  8. N Engl J Med. 1992 Jan 9;326(2):90-4 - PubMed
  9. Int J Impot Res. 2003 Aug;15(4):258-66 - PubMed
  10. J Urol. 2000 Feb;163(2):460-3 - PubMed
  11. J Urol. 1995 Mar;153(3 Pt 1):818-25 - PubMed
  12. Am J Physiol. 1995 Apr;268(4 Pt 1):C799-822 - PubMed
  13. Clin Sci (Lond). 2001 Jan;100(1):55-60 - PubMed
  14. Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4232-9 - PubMed
  15. Basic Clin Pharmacol Toxicol. 2006 Nov;99(5):360-4 - PubMed
  16. Vascul Pharmacol. 2002 Jan;38(1):61-71 - PubMed
  17. Nature. 1998 Nov 19;396(6708):269-72 - PubMed
  18. J Pharmacol Sci. 2006 May;101(1):85-90 - PubMed
  19. Gen Pharmacol. 1996 Mar;27(2):363-6 - PubMed
  20. Nat Rev Neurosci. 2006 Dec;7(12):921-31 - PubMed
  21. Circ Res. 2000 Jul 21;87(2):160-6 - PubMed
  22. Physiology (Bethesda). 2006 Feb;21:69-78 - PubMed
  23. J Physiol. 1999 Mar 15;515 ( Pt 3):639-51 - PubMed
  24. Urology. 2004 Apr;63(4):800-5 - PubMed
  25. J Ethnopharmacol. 2011 Oct 11;137(3):1366-72 - PubMed
  26. Eur Urol. 2007 Dec;52(6):1590-600 - PubMed
  27. BJU Int. 2012 May;109(9):1404-13 - PubMed
  28. J Androl. 2002 Sep-Oct;23(5):S10-9 - PubMed
  29. J Physiol. 1996 Apr 15;492 ( Pt 2):419-30 - PubMed
  30. Vascul Pharmacol. 2003 Jan;40(1):23-8 - PubMed
  31. J Sex Med. 2004 Jul;1(1):6-23 - PubMed
  32. J Androl. 1993 Sep-Oct;14(5):319-28 - PubMed
  33. Int J Impot Res. 2005 Jan-Feb;17(1):27-32 - PubMed
  34. J Urol. 1994 Jan;151(1):54-61 - PubMed
  35. Science. 1992 Jul 17;257(5068):401-3 - PubMed
  36. BJU Int. 1999 Jul;84(1):50-6 - PubMed
  37. Clin Sci (Lond). 2000 May;98(5):537-43 - PubMed
  38. J Pharmacol Sci. 2008 Sep;108(1):124-30 - PubMed

Publication Types